Endpoints for randomized controlled clinical trials for COVID-19 treatments
暂无分享,去创建一个
Michael Proschan | Thomas Jaki | Bin Cao | Lori E Dodd | Dean Follmann | Sally Hunsberger | Jing Wang | Tyler Bonnett | Franz Koenig | M. Proschan | L. Dodd | D. Follmann | Ye-ming Wang | B. Cao | T. Jaki | F. Koenig | Jing Wang | S. Hunsberger | Tyler Bonnett | Mat Makowski | F. Mentré | Drifa Belhadi | C. Schoergenhofer | D. Belhadi | France Mentre | Yeming Wang | Lisa L Korn | Christian Schoergenhofer | Mat Makowski | L. Korn | M. Makowski
[1] E. Korn,et al. Choice of column scores for testing independence in ordered 2 X K contingency tables. , 1987, Biometrics.
[2] P. Taba,et al. The need for neurologists in the care of COVID‐19 patients , 2020, European Journal of Neurology.
[3] D. Gommers,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.
[4] Patrick Royston,et al. The cost of dichotomising continuous variables , 2006, BMJ : British Medical Journal.
[5] Risk factors for gastrointestinal bleeding in critically ill patients , 1994 .
[6] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[7] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[8] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.
[9] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[10] Bernd Weissmuller,et al. Trials , 2020, Israelpolitik.
[11] Stephen Senn,et al. Measurement in clinical trials: A neglected issue for statisticians? , 2009, Statistics in medicine.
[12] D. Hedeker. A mixed‐effects multinomial logistic regression model , 2003, Statistics in medicine.
[13] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[14] Martin Posch,et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19 , 2020, Statistics in biopharmaceutical research.
[15] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[16] J. Saver. Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials , 2007, Stroke.
[17] H. Hou,et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. , 2020, JCI insight.
[18] J. Powers,et al. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization , 2019, Contemporary clinical trials communications.
[19] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[20] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[21] M. Wolff,et al. Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. , 2000, American journal of respiratory and critical care medicine.
[22] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[23] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[24] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[25] J. Powers,et al. Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization , 2017, Clinical trials.
[26] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[27] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[28] Risk Factors for Gastrointestinal Bleeding in Critically Ill Patients , 1994 .
[29] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.